These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1071 related items for PubMed ID: 18447663

  • 1. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE, Umland EM.
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [Abstract] [Full Text] [Related]

  • 2. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.
    J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620
    [Abstract] [Full Text] [Related]

  • 8. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.
    Eur Urol; 2008 Nov 01; 54(5):1066-72. PubMed ID: 18602738
    [Abstract] [Full Text] [Related]

  • 9. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE, Canadian Association of Oral and Maxillofacial Surgeons.
    J Rheumatol; 2008 Jul 01; 35(7):1391-7. PubMed ID: 18528958
    [Abstract] [Full Text] [Related]

  • 10. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM.
    Oncologist; 2008 Aug 01; 13(8):911-20. PubMed ID: 18695259
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ.
    J Oral Maxillofac Surg; 2007 Jul 01; 65(7):1328-31. PubMed ID: 17577497
    [Abstract] [Full Text] [Related]

  • 13. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R, Need A, Hughes T, Goss A.
    J Oral Maxillofac Surg; 2009 Jun 01; 67(6):1167-73. PubMed ID: 19446200
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
    Siddiqi A, Payne AG, Zafar S.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep 01; 108(3):e1-8. PubMed ID: 19570696
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
    Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, Patrikidou A, Triaridis S.
    J Clin Oncol; 2008 Oct 01; 26(28):4634-8. PubMed ID: 18574158
    [Abstract] [Full Text] [Related]

  • 17. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
    Dickinson M, Prince HM, Kirsa S, Zannettino A, Gibbs SD, Mileshkin L, O'Grady J, Seymour JF, Szer J, Horvath N, Joshua DE.
    Intern Med J; 2009 May 01; 39(5):304-16. PubMed ID: 19220531
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates and jaw osteonecrosis: the UAMS experience.
    Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC.
    Otolaryngol Head Neck Surg; 2007 Mar 01; 136(3):396-400. PubMed ID: 17321866
    [Abstract] [Full Text] [Related]

  • 19. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
    Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS.
    Crit Rev Oncol Hematol; 2007 Dec 01; 64(3):198-207. PubMed ID: 17855108
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.